NCT04156100 - A Study in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

April 8, 2021

Study Completion Date

September 29, 2021

Conditions

Advanced Solid Tumor

Interventions

DRUG

AGEN1223

AGEN1223 is a bispecific antibody.

DRUG

AGEN1223 and balstilimab

AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.

Trial Locations (4)

Abramson Cancer Center at the University of Pennsylvania, Philadelphia

University of Miami/Sylvester Comprehensive Cancer Center, Miami

HonorHealth Research Institute, Scottsdale

University of Southern California, Los Angeles